MedTrace Logo

Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)

NCT03091933 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-12-06

No results posted yet for this study

Summary

This study will evaluate the safety of infusing an anti-MiHA T cell line in patients suffering from an hematologic malignancy that has relapsed following hematopoietic stem cell transplantation from a matched donor.

Conditions

  • Hematologic Cancer
  • Relapse Leukemia
  • Relapsed Adult ALL
  • Relapsed Adult AML
  • Relapsed CLL
  • Relapsed Non Hodgkin Lymphoma
  • Relapsed Hodgkin's Lymphoma
  • Relapsed Myelodysplastic Syndromes
  • Relapsed Multiple Myeloma

Interventions

BIOLOGICAL

GLIDE

Gudide Lymphocyte by Immunopeptide Derived Expansion (GLIDE) is an anti- Minor histocompatibility (MiHA) cell line

Sponsors & Collaborators

  • Ciusss de L'Est de l'Île de Montréal

    lead OTHER

Principal Investigators

  • Denis-Claude Roy, MD PhD · CIUSSS d l'Est-de-l'Île-de-Montréal

  • Jean-Sébastien Delisle, MD PhD · CIUSSS d l'Est-de-l'Île-de-Montréal

  • Silvy Lachance, MD · CIUSSS d l'Est-de-l'Île-de-Montréal

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-06
Primary Completion
2018-03-31
Completion
2019-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03091933 on ClinicalTrials.gov